Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM. Target: NRTIs; HIV Didanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy.
Reverse Transcriptase Inhibitors Related Prodcuts:
Dapivirine; Tenofovir; Emtricitabine; Entecavir; Entecavir hydrate; Adefovir; Adefovir dipivoxil; Nevirapine; Lamivudine; Stavudine; Telbivudine; Etravirine; Zidovudine; Zalcitabine; Alovudine